Articles tagged with Flu Vaccines
Dr. Baozhong Wang is developing a multivalent layered nanocluster vaccine that can act against multiple influenza virus strains, using conserved antigenic proteins from both A and B viruses. The goal is to induce broadly reactive immune responses providing cross-protection against both influenza A and B viruses.
Researchers found no vaccine infections or disease flares in children given live-attenuated booster vaccination while on immune suppressing therapies. The study supports the use of flu vaccine and other vaccinations in patients with rheumatic diseases.
A study published in Nature Medicine finds that targeting the stalk of the flu virus provides protection against infection. Researchers analyzed naturally occurring influenza cases and found that individuals with higher levels of stalk antibodies had a reduced risk of getting sick, correlating with a 42% reduction in influenza infection.
Researchers found that people with higher levels of HA stem antibodies are less likely to become infected with influenza virus. The study suggests that the level of HA stem antibodies can be used as an indicator of protection against influenza virus infection.
A new study suggests that the Spanish influenza may have emerged in 1915-1916, rather than 1918, and that a vaccine could have been effective in treating it. The study found that the virus likely originated from aquatic geese and ducks, and that it underwent significant mutations before becoming pandemic.
Researchers will study how young children's immune systems respond to initial influenza infection and vaccination, aiming to understand immune memory and develop more effective vaccines. The studies may uncover insights into 'immunologic imprinting' and its impact on future infections.
Scientists have developed a new single vaccination approach that simultaneously protects against both influenza and pneumococcal infections, overcoming the limitations of current vaccines. The approach combines vaccines targeting different components of the virus and bacteria, inducing enhanced cross-protective immunity.
A $30 million federal grant will accelerate the search for a universal flu vaccine that can provide longer-lasting protection. The study, which involves over 2,000 sets of mothers and infants from the US and Mexico City, aims to understand how the immune system responds to first flu virus exposures.
A new systematic review provides a comprehensive update on vaccine safety science, assessing 47 adverse events following immunization (AEFI). The study found that 12 AEFIs have been established to have causal relationships with at least one vaccine currently recommended in the US population.
A new AAP PROS study assesses influenza vaccine hesitancy among caregivers of children who received the first dose. Researchers found that over 90% of caregivers believed their child would be 'protected with only one flu shot,' and 12% had moderate/high vaccine hesitancy.
A new study reveals that vaccination in immunocompromised children is suboptimal due to lack of knowledge and concern for triggering a disease flare. The majority of patients received vaccines from their primary care physician or health department, but there were significant barriers to completing vaccines.
A new vaccine approach could protect against pandemic flu by teaching the immune system to recognize the shared 'cone' portion of the flu virus, rather than just the seasonal 'scoop'. Researchers have shown early promising results in lab animals.
The article review found no risks associated with breastfeeding mothers receiving routine and standard vaccinations. In fact, there are benefits for both mothers and infants, including enhanced antibody response and reduced vaccine-related fever after infant vaccination.
A potent and safe vaccine protects against MERS, a viral infection with a 35% mortality rate in 27 countries. The new vaccine platform targets specific cells without causing lung damage, offering a promising strategy for enhancing vaccine safety and potency.
Experts discuss ongoing research on improving seasonal influenza vaccines and developing a universal vaccine for long-term protection against multiple seasonal and pandemic influenza viruses. Recent scientific advances have provided unprecedented momentum toward this goal.
The report identified major barriers to influenza immunization among racial minorities, including older adults with low socioeconomic status and chronic health conditions. To address these gaps, Sustainable Healthy Communities launched a population health initiative, DRIVE, aiming to improve immunization rates in underserved communities.
According to a study published in the Canadian Medical Association Journal, vaccine allergies are extremely uncommon, affecting only one in 760,000 vaccinations. Most side effects from vaccines are not allergic reactions, but rather minor responses that can be managed with over-the-counter medications.
A study found that a common food additive, tert-butylhydroquinone (tBHQ), can hinder the immune system's ability to fight off flu viruses, making vaccines less effective. In mice exposed to tBHQ, CD4 and CD8 T cells showed reduced functionality, leading to increased inflammation and mucus production in the lungs.
The NIH has launched a Phase 1 clinical trial to evaluate the safety and immune response of an experimental universal influenza vaccine candidate. The vaccine, known as H1ssF_3928, is designed to induce immunity against diverse influenza subtypes by focusing on a portion of the virus that varies relatively little from strain to strain.
InDevR launches first-in-class reagent kit for rapid quantification of N9 in 'pandemic' influenza vaccines. The VaxArray assays are expected to reduce time and cost associated with vaccine production, facilitating improvement of seasonal and pandemic influenza vaccines.
A study published in Cell Host & Microbe found that antibodies from previous exposures to flu viruses can enhance the immune system's response to new strains, potentially reducing the need for annual vaccinations. The researchers discovered that more than 70% of persistent antibodies targeted invariant parts of the virus.
A University of Pittsburgh analysis reveals that waiting until October to get flu shots may save thousands of lives. The study found that compressed vaccination periods starting in October can prevent up to 22,062 cases of flu and save as many as 258 lives compared to status quo vaccination timing.
Researchers discover that targeting a specific protein called neuraminidase (NA) in flu vaccines can induce a broader protective response against influenza type B viruses. This finding suggests a potential way to boost the efficacy of current vaccines and develop a universal flu vaccine.
A large study of nearly 30 million hospital records shows that people who got a flu shot while hospitalized had a 10 percent lower risk of having a heart attack compared to those who didn't get vaccinated. The findings suggest that getting a flu vaccine can reduce the risk of major cardiovascular problems.
A researcher at Georgia State University has received a $3.86 million grant to develop a universal flu vaccine using a microneedle patch that can protect against any strain of the influenza virus. The vaccine aims to induce strong cross-immune protection and overcomes seasonal flu limitations, which have been ineffective in recent years.
The elderly are more susceptible to the flu due to a lack of antibody diversity, which reduces their ability to adapt to new viral strains. Antibodies from elderly individuals target only conserved proteins and structures, making it harder for them to protect against evolving viral strains.
InDevR's new VaxArray kit offers a standardized method to measure neuraminidase in influenza vaccines, improving accuracy and precision. This assay is expected to aid in the development of more broadly protective flu vaccines by enabling manufacturers to meet current regulatory requirements.
Immunology researchers at the Babraham Institute discovered how lung tissue is remodelled to support an immune response to influenza, producing antibodies with cross-protection against multiple strains. The findings may lead to more robust seasonal influenza vaccination and new therapeutic strategies for autoimmune diseases.
A recent study published in CHEST reveals that influenza vaccination can reduce hospitalizations among patients with chronic obstructive pulmonary disease (COPD) by up to 38%. The study found that nearly two-thirds of COPD patients were not vaccinated, highlighting the need for improved vaccination rates and timely antiviral medication...
A recent Kaiser Permanente study found that hospitalized patients who received the flu vaccine had no increased risk of outpatient visits or hospital readmission within seven days of discharge. The study also showed that vaccinating hospital patients did not increase the risk of fever or rates of laboratory evaluations for infection.
A study recommends replenishing vaccine stocks in regions where they are being used up, rather than sending them to areas with low vaccination rates. This tweak could save thousands of lives in both regular flu seasons and pandemics, reducing the spread of the flu virus and secondary infections.
A recent study by FSU researchers found significant racial disparities in flu vaccine rates among adolescents. Black teens received significantly lower vaccination rates than their white and Hispanic peers. The researchers suggest targeted interventions to improve vaccination rates and reduce disparities.
Researchers analyzed severe influenza cases in Catalan hospitals to study vaccination effectiveness in reducing ICU admissions and deaths. Vaccination showed 23% effectiveness overall, with 44% for those over 65.
The project leverages the multiplexed VaxArray platform to deliver high-quality MR vaccines faster and at lower production costs. Measles and rubella vaccines can prevent these highly contagious diseases, which have had a significant impact globally.
Researchers at Scripps Research have discovered a potential new approach to prevent influenza virus infections by tethering four antibodies together, showing cross-reactivity against all types of influenza. The therapeutic candidate has been shown to offer protection against multiple strains of the virus in mice.
A groundbreaking new study aims to understand the human immune system's response to influenza by analyzing gene regulation, microbiome influence, and other factors. Researchers will take comprehensive measurements from healthy participants who receive a standard influenza vaccination.
A new study suggests that high-dose influenza vaccine is associated with lower risk for hospitalizations in kidney failure patients on dialysis. The findings indicate a significant reduction in hospitalizations among dialysis patients who received the high-dose vaccine, while standard dose vaccine showed no difference.
Researchers developed a novel DNA vaccine that protected mice against multiple H3N2 viruses and severe illness, offering a promising approach to elicit an immune response against diverse strains. The vaccine strategy represents a step forward in eliminating the need for seasonal reformulation of influenza vaccines.
InDevR's VaxArray Influenza Pandemic HA potency assay enables rapid assessment of vaccine potency, reducing bottlenecks in vaccine production and administration. The assay demonstrates high sensitivity, accuracy, precision, and detection of a large panel of influenza viruses with pandemic potential.
The University of Montana has been awarded a $10 million contract to develop a universal flu vaccine. The project aims to improve both seasonal and pandemic flu vaccines by utilizing a synthetic dual-TLR adjuvant combination system called TRAC-478.
Researchers at the University of Oxford have demonstrated pre-clinical success for a universal flu vaccine by identifying regions of limited variability in the influenza virus. The vaccine targets these regions, which are targeted by the immune system and can induce cross-reactivity to historical strains.
Internal GlaxoSmithKline reports suggest a large discrepancy in adverse event reporting for Pandemrix compared to other GSK pandemic influenza vaccines. The BMJ investigation raises questions about the transparency of information surrounding the vaccine's safety, with significant implications for public health.
A Phase 1 clinical trial is testing the safety and immune-stimulating ability of an experimental nasal influenza vaccine in healthy children and teens. The investigational vaccine, developed by FluGen, Inc., has been designed to replicate only once in the body and prompt a robust immune response.
Researchers found vaccination rates dropped significantly throughout the day at primary care clinics from 44% to 32%. Implementing a nudge in electronic health records increased flu vaccinations by nearly 20% compared to practices with no intervention.
Researchers developed an adjuvanted intradermal flu vaccine that protected ferrets and humans against lethal pandemic flu strains. The vaccine, which can be self-administered via a microneedle, shows promise for rapid production and distribution during pandemics.
A synthetic DNA vaccine has been shown to produce broad immune responses against diverse H3N2 viruses, which have led to high morbidity and mortality in recent years. The vaccine was found to be more effective than traditional vaccines in protecting mice from lethal influenza A infection.
A Phase 1 clinical trial is underway to evaluate the immune-boosting properties of imiquimod cream in combination with an H5N1 influenza vaccine. The study aims to enhance the immune response conferred by the pre-pandemic vaccine, potentially reducing the number of doses required to achieve sufficient immunity.
A modified RNA vaccine elicits protective response in mice to a conserved region of the flu virus, providing broad protection against various strains. The vaccine has shown promise as a universal flu vaccine candidate, which could be given multiple times over a lifetime for long-lasting protection.
A double-layered nanoparticle vaccine made with peptides has been found to effectively protect mice against the influenza A virus. The vaccine triggers immune responses of both B and T lymphocytes, providing broad cross-protection against a wide range of diverse influenza viruses.
Researchers at NIAID developed a 3D model of the 1918 H1 pandemic influenza virus using cryo-electron microscopy. The study found that VLPs are mostly composed of hemagglutinin proteins, influencing vaccine efficacy.
The VaxArray NA reagent kit provides a standardized method for assessing neuraminidase in influenza vaccines, enabling manufacturers to meet current regulatory requirements and prepare for future trends. This breakthrough tool is expected to serve as an important new asset in the push for a more broadly protective or 'universal' flu va...
A new study suggests that vaccinating asthmatic children against the flu could significantly reduce their risk of needing hospitalization for an asthma attack. The study found that kids with influenza or parainfluenza had a 37-per-cent or more chance of not responding to treatment, compared to 13 per cent for children without a virus.
Most non-VA hospitals now require flu vaccination, with nearly 70% of institutions mandating the shot. In contrast, only 4% of VA hospitals have a similar requirement. Vaccination mandates are more effective in reaching high vaccination rates among healthcare workers.
A survey of pediatricians found that delays in receiving influenza vaccine from private and VFC stock pose problems, with 56% delaying vaccinations for patients whose vaccines are out of stock. This highlights the need for systematic changes to address these delays and increase uptake of influenza vaccine among children.
A Phase 2 clinical trial has started in the US to test an experimental universal influenza vaccine, M-001, for its safety and ability to produce broad protective immune responses. The trial aims to provide durable protection against multiple influenza strains, including those that might cause a pandemic.
The Scripps Research team will expand studies on broadly neutralizing antibodies that can neutralize many strains of malaria and influenza. The grant aims to design promising vaccine candidates against these diseases, which kill millions globally each year.
University of Rochester researchers have developed a new live equine influenza vaccine that is safe and more protective than existing vaccines. The vaccine targets the H3N8 strain currently circulating in North America and Europe, and was shown to protect horses against the virus in a small study.
At 43% vaccine coverage, a low-efficacy vaccine (20% effective) could avert over 20 million infections, 61,000 deaths, and 2.2 million lost DALYs in the US. The optimal strategy involves targeting elderly populations as efficacy decreases.
A new study shows a predictive link between VaxArray-measured potency and vaccine-induced immunogenicity in mice. The study found strong correlations between VaxArray assays and serum levels of antibodies targeting influenza hemagglutinin and neuraminidase.
A new study by Penn Medicine neurologist Amit Bar-Or presents findings on ocrelizumab's impact on multiple sclerosis patients, including reduced inflammation and lower vaccine response levels. The research also explores the role of ocrelizumab in limiting MS attacks.